Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on the discovery and development of treatments for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. Their flagship product is RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ALS in adults in the United States. It is also marketed as ALBRIOZA for the treatment of ALS in Canada. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. Community Guidelines: https://bit.ly/3C1v1wz 

Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

The ALS Association

ALS Finding a Cure

Lysosomal Therapeutics

Morningside Group

ALS Investment Fund

Morningside Venture Investments

DRADS Capital

Woodline Partners

Marshall Wace

Perceptive Advisors

Polaris Founders Capital

Tybourne Capital Management

Verition Fund Management

683 CAPITAL

aMoon Fund

Belinda Termeer

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com. 

With a new year upon us, we’re eager to continue our fight of addressing the unmet needs of those with #ALS and other #neurodegenerative diseases. There is no time to waste.

Today we announced the first participant dosed in the largest #progressivesupranuclearpalsy study to date. This Phase 3 #clinicaltrial for the treatment of #PSP will enroll approximately 600 participants across ~100 sites in the U.S., Canada, the EU, the UK, and Japan.
Read more: https://lnkd.in/enCfTTKU 

As 2023 draws to a close, we’re also reflecting on 10 years of Amylyx. We’d like to show our gratitude to the incredible determination of the #ALS and #neurodegenerative community, as well as our extraordinary global colleagues who show up every day with the shared mission of one day ending the suffering caused by neurodegenerative diseases.

At Amylyx, we’ve created a culture that uses unconventional thinking for unsolved problems. We learn from one another through our collective experience, and we share a connection in our common purpose. 
Does this sound like you? 
See our current openings: https://lnkd.in/eDq_3vK4 

COM:AMYLYX

Amylyx Pharmaceuticals, Inc.

Last Close

2.12

30/08 20:00

Market Cap

140.77M

Beta: -

Volume Today

407.84K

Avg: -

locale

market

industry

website

crunchbase

linkedin

founding date

ipo date

peer of

Metrics